Nevirapine Teva B.V.

Nevirapine, the active ingredient in Nevirapine Teva B.V., is a non‑nucleoside reverse transcriptase inhibitor presented as an oral dosage form for oral use. It is employed in the treatment of HIV‑1 infection in adults and children as part of combination antiretroviral therapy.

GNH USA supplies Nevirapine Teva B.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral medication that targets the HIV‑1 reverse transcriptase enzyme, reducing viral replication in infected individuals. - HIV‑1 infection (treatment‑naïve adults): lowers viral load and helps restore immune function. - HIV‑1 infection (treatment‑experienced adults): maintains virologic suppression when combined with other antiretrovirals. - Pediatric HIV‑1 infection (children ≥ 2 years): contributes to viral suppression as part of a combination regimen.

Nevirapine may cause a range of adverse reactions, from mild to severe. Patients should be monitored for any new symptoms during therapy.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal upset. - Fatigue: feeling of tiredness. - Headache: mild to moderate intensity. - Abdominal pain: discomfort in the stomach area. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate discontinuation. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Hepatic failure: marked liver enzyme elevation or liver injury. - Severe hypersensitivity: systemic allergic response. - Neutropenia: significant reduction in white blood cells. - Pancreatitis: inflammation of the pancreas.

Before initiating Nevirapine, clinicians should assess baseline health status and monitor for specific risks. - Liver function monitoring: obtain baseline tests and repeat periodically. - Rash assessment: discontinue if severe or progressing. - Hepatitis B co‑infection: evaluate risk of reactivation. - Known hypersensitivity: avoid in patients with prior allergic reactions to nevirapine. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Nevirapine interacts with several medicines that can alter its plasma levels or increase toxicity.

Major Interactions (Avoid): - Rifampin: induces metabolism, reducing nevirapine exposure. - Ritonavir‑boosted protease inhibitors: increase nevirapine concentrations, raising toxicity risk. - St. John's wort: strong enzyme inducer that lowers nevirapine levels. - Didanosine: combined use may increase gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: nevirapine may reduce hormonal efficacy. - Warfarin: potential alteration of INR values. - Methadone: nevirapine can lower methadone concentrations. - Azole antifungals: may increase nevirapine levels, requiring dose adjustment.